Drugs for postmenopausal osteoporosis.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D002116:Calcitonin / Q000009:adverse effects / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use*; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D004366:Nonprescription Drugs / Q000009:adverse effects / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D055553:Prescription Drugs / Q000009:adverse effects / Q000627:therapeutic use; D053245:RANK Ligand / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014807:Vitamin D / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004338:Drug Combinations; D004967:Estrogens; D004366:Nonprescription Drugs; D010281:Parathyroid Hormone; D055553:Prescription Drugs; D053245:RANK Ligand; D014807:Vitamin D; D000069448:Denosumab; D002116:Calcitonin; D002118:Calcium